H.C. Wainwright analyst Edward White notes 60 Degrees Pharma has announced that Investigational Review Board approval has been granted for the company’s planned double-blind, placebo-controlled Phase 2a study of Arakoda for the treatment of hospitalized babesiosis patients. Arakoda is the company’s antimalaria medicine indicated for the prophylaxis of malaria in patients aged 18 years and older. The firm believes babesiosis could offer a much larger potential commercial opportunity than malaria. 60 Degrees also announced that the FDA has rescheduled the previously announced January 15, 2024, Type C meeting to January 17, 2024, due to the Martin Luther King Jr. federal holiday. H.C. Wainwright has a Neutral rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SXTP:
- 60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
- 60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease
- 60 Degrees Pharmaceuticals announces Type C Meeting with FDA for tafenoquine
